Prelude Therapeutics (PRLD) Expected to Announce Earnings on Monday

Prelude Therapeutics (NASDAQ:PRLD) is expected to be posting its Q4 2025 results before the market opens on Monday, March 9th. Analysts expect the company to announce earnings of ($0.33) per share and revenue of $20.50 million for the quarter. Investors can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Thursday, March 12, 2026 at 1:30 PM ET.

Prelude Therapeutics Stock Performance

Shares of NASDAQ:PRLD opened at $2.76 on Monday. Prelude Therapeutics has a 52 week low of $0.61 and a 52 week high of $4.22. The company’s fifty day moving average is $2.34 and its 200-day moving average is $1.75. The company has a market capitalization of $173.52 million, a PE ratio of -1.88 and a beta of 0.79.

Analyst Upgrades and Downgrades

PRLD has been the topic of a number of recent analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Prelude Therapeutics in a research report on Thursday, January 22nd. Wall Street Zen cut shares of Prelude Therapeutics from a “buy” rating to a “hold” rating in a research note on Sunday, January 18th. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $4.00.

Hedge Funds Weigh In On Prelude Therapeutics

Institutional investors have recently modified their holdings of the stock. AQR Capital Management LLC grew its stake in shares of Prelude Therapeutics by 170.7% during the first quarter. AQR Capital Management LLC now owns 33,823 shares of the company’s stock valued at $26,000 after purchasing an additional 21,330 shares during the last quarter. Acadian Asset Management LLC lifted its holdings in Prelude Therapeutics by 9.1% during the 1st quarter. Acadian Asset Management LLC now owns 529,327 shares of the company’s stock worth $405,000 after buying an additional 43,946 shares in the last quarter. XTX Topco Ltd boosted its position in Prelude Therapeutics by 72.4% in the 2nd quarter. XTX Topco Ltd now owns 42,573 shares of the company’s stock valued at $34,000 after buying an additional 17,873 shares during the last quarter. Marshall Wace LLP acquired a new stake in shares of Prelude Therapeutics in the 2nd quarter valued at $34,000. Finally, Jane Street Group LLC bought a new stake in shares of Prelude Therapeutics during the second quarter worth $74,000. 79.72% of the stock is owned by institutional investors.

About Prelude Therapeutics

Prelude Therapeutics Incorporated is a clinical-stage precision medicine company focused on the discovery and development of small molecule therapies for genetically defined oncology targets. By leveraging a chemical biology approach, the company aims to deliver targeted treatments that address key drivers of cancer cell growth and survival. Prelude’s pipeline emphasizes novel inhibitors designed to engage molecular pathways validated by both preclinical and clinical evidence.

Among Prelude’s lead programs is PRT2527, a selective PI3K‐alpha/delta inhibitor in Phase 1 clinical trials for solid tumors harboring PIK3CA and other pathway mutations.